跳到正文
原文
NEJM· @NEJM · X·· 11 天前AI 评分42
AI 导读

过去5年急性缺血性卒中静脉溶栓的最大变化之一是替奈普酶使用增加、逐步取代阿替普酶。替奈普酶纤维蛋白特异性更高、半衰期更长,可单次团注给药而无需阿替普酶那样的1小时输注;试验显示两者临床获益与安全性基本相当,替奈普酶不劣于阿替普酶,2025年FDA据此批准其用于急性缺血性卒中。FDA批准的分层剂量方案也使快速确定剂量更为便捷。

正文

Among the biggest changes in intravenous thrombolysis practice in the past 5 years has been the increased use of tenecteplase over alteplase. Tenecteplase, a slightly modified form of tissue plasminogen activator, has more fibrin specificity and longer half-life than alteplase and therefore can be given more conveniently as a single bolus rather than the one-hour infusion needed for alteplase. In the past decade, tenecteplase has been tested in comparison with alteplase in patients with acute ischemic stroke. Although tenecteplase may result in higher rates of recanalization, trials have shown that clinical outcomes are essentially equivalent between the two drugs — or at least the conclusion can be made that tenecteplase is noninferior to alteplase in terms of benefit and safety. Largely on the basis of these noninferiority results, in 2025, the FDA approved the use of tenecteplase in patients with acute ischemic stroke. Although accurate patient weight is important to establish doses for both alteplase and tenecteplase, the tiered dosing of tenecteplase that was approved by the FDA (seen in table) makes rapid determination of the appropriate dose easier.

Read the Review Article “Intravenous Thrombolysis for Acute Ischemic Stroke — New Directions”: https://nej.md/4iuL5Lr

来源:NEJM · x.com